WockAIR® maintenance therapy in asthma and COPD¹
Each dose contains two compounds for the treatment of asthma or COPD¹
WockAIR® is a combination inhaler (a preventer and long-acting reliever in a single inhaler), and contains two molecules: budesonide and formoterol fumarate dihydrate which are used to treat asthma in adults and adolescents aged 12-17 years, and Chronic Obstructive Pulmonary Disease (COPD) in adults aged 18 and over¹
Budesonide works by reducing and preventing swelling and inflammation in the lungs and formoterol fumarate dihydrate works by relaxing the muscles in the airway.
For asthma the required dose of each component of WockAIR® is individual and should be adjusted to the severity of the disease. The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. WockAIR® is not intended for the initial management of asthma and is not recommended for children younger than 12 years.
Maintenance and reliever therapy (MART) in asthma¹
With MART in asthma, patients take a daily maintenance dose of WockAIR® and in addition take WockAIR® as needed in response to symptoms. Meaning both treatments in one handy device.
MART administration applies to the 160/4.5 inhaler only.
Patients should be advised always to have WockAIR® available for rescue use.
No more than 6 inhalations should be taken on any single occasion. A total daily dose of up to 12 inhalations could be used for a limited period. Patients using more than 8 inhalations daily should be strongly recommended to seek medical advice. They should be reassessed and their maintenance therapy should be reconsidered.¹
1. WockAIR® Summary of Product Characteristics